Skip to main
OCS

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding is a leading biopharmaceutical company with a focus on sight-saving treatments for rare and common eye conditions. With multiple promising candidates, including OCS-01 for diabetic macular edema (DME), OCS-02 for dry eye disease (DED), and OCS-05 for acute optic neuritis (AON) and other neuro-ophtha disorders, the company is well-positioned for potential success in the market. Additionally, the recent Breakthrough Therapy designation for OCS-05 in ON and the ongoing PIONEER-1 study in ON have the potential to significantly expand the company's market reach and value. Strong financials, a robust pipeline, and a strategic global presence make Oculis a compelling investment opportunity.

Bears say

Oculis Holding is a promising biopharmaceutical company with a diverse pipeline of treatments for various eye disorders. While their precision medicine approach for DED and potential breakthrough therapy designation for privosegtor in AON highlight their innovative solutions, the company's slow enrollment in pivotal trials and lack of notable financials make it a risky investment. Additionally, with a small addressable population for its target market, the company may struggle to generate significant profits.

OCS has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 7 analysts, OCS has a Strong Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.